TX-ABB
9.10.2019 17:02:09 CEST | Business Wire | Press release
ABB today opened its first global healthcare research hub on the Texas Medical Center (TMC) campus, in Houston, Texas – showcasing a number of concept technologies, including a mobile YuMi® robot, which will be designed to assist medical and laboratory staff with laboratory and logistics tasks in hospitals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191009005527/en/
The dual-arm mobile YuMi® will be able to sense and navigate its way around its human co-workers autonomously, while learning to find different routes from one location to another. It has the potential to undertake a wide range of repetitive and time-consuming activities, including preparation of medicines, loading and unloading centrifuges, pipetting and handling liquids and picking up and sorting test tubes.
The mobile YuMi®could also be used in hospitals for a wide variety of logistics roles. YuMi® may be able to dispense medicines, transport them to where they are needed in hospitals, bring medical supplies to hospital staff and bed linen direct to patients’ bedrooms.
At TMC Innovation Institute, ABB will develop robots that are able to carry out repetitive, delicate and mundane processes, leaving highly skilled medical and laboratory staff free to undertake more valuable roles and ultimately treat more patients. ABB analysis shows that repetitive tasks could be completed up to 50 per cent faster with automation, compared to current manual processes, with the added benefit that robots can work 24 hours a day.
“The healthcare sector is undergoing significant transformation as the diagnosis and treatment of disease advances, while coping with an aging population, increasing costs and a growing worldwide shortage of medical staff. With our new healthcare research and development hub at TMC we are aiming to develop answers to these challenges – together with the best minds in academia, science and medicine,” said Sami Atiya, President of ABB’s Robotics and Discrete Automation business. “Our experience in industrial and collaborative robotics will give us a strong basis to be able to adapt flexible automation to the healthcare sector. Together with our partners at TMC, we will develop cutting-edge robotics solutions. We are working to reduce the number of manual procedures performed by medical staff, improve the accuracy of laboratory work and enhance patient satisfaction and ultimately patient safety.”
Other technologies showcased by ABB at the Healthcare Research Hub include YuMi® robots that could aid in centrifuge tending and test tube handling systems, and an IRB 1200 robot that could execute liquid transfers in a pipetting application. All are common medical laboratory tasks that robotic automation may be able to support by combining consistent performance with a level of flexibility and continuous operation that could increase throughput and quality while minimizing costs.
TMC is the largest medical city in the world with world-class collaborative research resources, including some of the world’s leading companies and hospitals. ABB’s new 5,300 sq ft (500m2 ) Healthcare Hub will be housed at the TMC Innovation Institute, a state-of-the-art hub that fosters collaboration of medicine and cutting-edge technology, connecting start-ups with pioneers in academia and leading technology companies in order to accelerate the development and prototyping of breakthrough medical technology.
“Texas Medical Center, TMC Innovation, and the entire TMC network of member institutions are pleased to welcome ABB on the occasion of its first foray into the healthcare space with this incredible and unprecedented new robotics facility,” emphasized Bill McKeon, President & CEO of Texas Medical Center. He added, “A primary goal across TMC – the largest medical city in the world – is to make research happen faster while simultaneously cutting costs in order to create more rapid and cost-effective solutions for patients who are in desperate need of treatment. ABB’s move into the heart of the Texas Medical Center campus with this first-of-its-kind R&D facility for creating robotics solutions in healthcare will set a new course for advancements in medicine and establish TMC as the nexus for a new kind of synergistic partnership that will shape the future of healthcare for clinicians, researchers, and patients alike.”
Robotic automation in the healthcare sector offers significant opportunity for future growth. According to internal ABB research, the global market is estimated to reach nearly 60,000 non-surgical medical robots by 2025, a fourfold increase from 2018.
Watch the video: https://youtu.be/SA_1vfH5UIk
Media b-roll: https://drive.google.com/file/d/13r9gjaXpLCZmJ69m6m6YyVDM9ONkauQO/view
ABB (ABBN: SIX Swiss Ex) is a technology leader that is driving the digital transformation of industries. With a history of innovation spanning more than 130 years, ABB has four customer-focused, globally leading businesses: Electrification, Industrial Automation, Motion, and Robotics & Discrete Automation, supported by the ABB Ability™ digital platform. ABB’s Power Grids business will be divested to Hitachi in 2020. ABB operates in more than 100 countries with about 147,000 employees. www.abb.com
ABB Robotics is a pioneer in industrial and collaborative robots and advanced digital services. As one of the world’s leading robotics suppliers, we are active in 53 countries and over 100 locations and have shipped over 400,000 robot solutions for a diverse range of industries and applications. We help our customers to improve flexibility, efficiency, safety and reliability, while moving towards the connected and collaborative factory of the future. www.abb.com/robotics
TMC INNOVATION
Texas Medical Center (TMC)—the largest medical city in the world—is at the forefront of advancing life sciences. Home to the brightest minds in medicine, TMC nurtures cross-institutional collaboration, creativity, and innovation among its 106,000-plus employees. With a campus of more than 50 million square feet, TMC annually hosts 10 million patients, performs over 180,000 surgeries, conducts over 750,000 ER visits, performs close to 14,000 heart surgeries, and delivers over 25,000 babies. Beyond patient care, TMC is pushing the boundaries of clinical research across its extensive network of partner institutions on a daily basis, pioneering effective health policy solutions to address the complex health care issues of today, and cultivating cutting-edge digital health applications and medical devices. For more information, please visit www.tmc.edu .
View source version on businesswire.com: https://www.businesswire.com/news/home/20191009005527/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BRUNO to Showcase Acclaimed Lifestyle and Travel Collections at Ambiente 20262.2.2026 09:00:00 CET | Press release
Tokyo-based lifestyle company BRUNO, Inc. (Headquarters: Shinjuku-ku, Tokyo; President & CEO: Tetsu Shiota), dedicated to the planning, development, and sale of lifestyle products, is pleased to announce its participation in Ambiente—the world’s leading international consumer goods trade fair held in Frankfurt, Germany. The company will showcase its two flagship brands: "BRUNO," a lifestyle brand dedicated to "enjoying life to the fullest," and "MILESTO," a premium travel brand designed for those who "live every day like a journey." This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260202663769/en/ Our participation in Ambiente marks a pivotal step in our global expansion strategy, as outlined in our current medium-term management plan. We are excited to introduce BRUNO and MILESTO—brands that have earned immense loyalty in Japan—to a global audience. Our exhibit showcases a curated selection of flagship products and latest inn
Reges Elektrik Acquires the Demirli Wind Power Plant, One of Türkiye’s Most Significant Wind Energy Projects2.2.2026 09:00:00 CET | Press release
Reges Elektrik, a dynamic and innovative leader in the Turkish energy sector, has announced the acquisition of Tuşpa Enerji Üretim A.Ş. as part of its strategic growth roadmap. Through this landmark acquisition, Reges Elektrik will launch electricity production at the 70 MW Demirli Wind Power Project, located in the Kaman district of Kırşehir. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126059611/en/ From left to right: Enver Altuncu, General Manager and Board Member at Reges Elektrik; Cansu Ünal Öngören, CFO and Board Member at Reges Elektrik; Geert Dooms, General Manager at RES Türkiye; Kağan Gilik, Deputy General Manager at RES Türkiye. Acquired from RES Türkiye, a subsidiary of RES Group—the world’s largest independent renewable energy company—the Demirli Project represents a pivotal milestone in Reges Elektrik’s decisive expansion into energy production. With this investment, the company scales its operations to i
Teledyne FLIR Defense Wins $17.5 Million Contract from armasuisse to Deliver Black Hornet 4 Nano-Drones for Dismounted and Vehicle-Integrated Reconnaissance2.2.2026 08:00:00 CET | Press release
Delivery of the Black Hornet UAV systems to Swiss Armed Forces will include drones with software and integration kit specially designed to work with Piranha 8x8 vehicle digital infrastructureWork shows promise and market potential for UAS armored vehicle integrations to enhance tactical operations Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE:TDY), announced that it has received a $17.5 million contract from armasuisse, the Swiss Federal Office of Defence Procurement, to deliver a large number of Black Hornet® 4 Personal Reconnaissance Systems, one of the world’s most advanced and widely deployed nano-drones. Black Hornet 4 was selected as an airborne dismountable Intelligence, Surveillance, and Reconnaissance (ISR) capability sensor for armasuisse’s Piranha 8x8 Armored engineering vehicle program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260201061637/en/ Teledyne FLIR Defense has won a $17.5
Danish C-UAS Startup Shotling Raises €700K Oversubscribed Pre-Seed (Myriad-IPO CLUB-EIFO) for Anti-Drone Shotgun2.2.2026 07:35:00 CET | Press release
Shotling, a Danish defense technology startup specializing in kinetic short-range counter-UAS (C-UAS) systems, today announced the closing of a pre-seed financing round with €700K committed out of a targeted €500K. The round is led by Myriad Defense Fund, with co-investment from IPO CLUB’s Fund II America 2030, and a non-dilutive match-loan granted by EIFO, the Export and Investment Fund of Denmark, supporting Shotling’s mission to deliver rapid-fire modular shotgun systems against FPV drones and loitering munitions—as the global counter-UAS market accelerates towards $10B by 2030, with kinetic defense segment showing strong momentum (25%+ CAGR). Shotling’s rotary shotgun system provides unmatched close-range defense (50–100m) against the rapidly growing threat of kamikaze drones, combining a gatling-style design, with novel, high-capacity magazines, and firing rates up to 3,000 RPM using standard or tungsten-based 12-gauge shells. With deep expertise in weapons engineering and active
Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission2.2.2026 07:00:00 CET | Press release
The United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults RelabotulinumtoxinA is designed to optimize molecule integrity to deliver fast onset of action as early as Day 1 and sustained results for six months for frown lines and crow’s feet and has been approved in over 20 markets, including in the European Union1-3 Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
